NDASPINALINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
MARCAINE (bupivacaine hydrochloride in dextrose) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 1984.
Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARCAINE (bupivacaine HCl in dextrose) is a long-acting local anesthetic administered via spinal injection to block nerve impulses and provide regional anesthesia. It works by increasing the electrical excitation threshold in nerves, slowing impulse propagation, and reducing action potential rise rate. Clinically used to induce loss of pain, temperature, touch, proprioception, and muscle tone in a selective, progressive manner.
$0.694MPart D
LOE ApproachingLong-established product nearing loss of exclusivity with minimal Part D volume; brand team likely focused on cost management and niche indication maintenance rather than growth.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty
Started Jun 2017
52 enrolled
Hernioplasty
Career Relevance
Working on MARCAINE offers limited career growth potential given LOE-approaching status and minimal Part D volume (66 claims, $0.7M spend in 2023). Roles focus on defensive market management, hospital formulary maintenance, and generic transition planning rather than brand building or indication expansion.
Brand Manager
Worked on MARCAINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.